1)日本肝臓学会 肝炎診療ガイドライン作成委員会(編):C型肝炎治療ガイドライン(第7版),2019
2)Kattakuzhy S, et al:Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers;A nonrandomized clinical trial. Ann Intern Med 167:311-318, 2017
3)Osawa M, et al:Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol 54:291-296, 2019
4)Izumi N, et al:Sofosbuvir—velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int 12:356-367, 2018
5)Takehara T, et al:Efficacy and safety of sofosbuvir—velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis;An open-label phase 3 trial. J Gastroenterol 54:87-95, 2019
6)Kumada H, et al:Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 53:566-575, 2018
7)Reig M, et al:Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy;A note of caution. J Hepatol 65:719-726, 2016
8)Ioannou GN, et al:HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol, 2017[epub ahead of print]
9)日本肝臓学会(編):慢性肝炎・肝硬変の診療ガイド2019,文光堂,2019
10)European Association for the Study of the Liver:EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69:461-511, 2018
11)Ghany MG, et al:Hepatitis C guidance 2019 update;AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology, 2019[epub ahead of print]